Antonios Trakatellis MEP_ Philip Whitehead MEP_ John Bowis MEP

Document Sample
Antonios Trakatellis MEP_ Philip Whitehead MEP_ John Bowis MEP Powered By Docstoc
					                                                                                                                                                                                                                                                                                                                        Abstract Ref No. 40


                        The Impact of Diagnosis Delays in Primary
                               Immunodeficiencies (PIDs)
A poster jointly submitted by the key organisations representing the EU and International PID nurse, patient and physician
  community: The European Society for Immunodeficiencies (ESID), The International Nurses Group for Immunodeficiencies
  (INGID), The International Patient Organisation for Immunodeficiencies (IPOPI), the European Federation of Immunological
                                   Societies (EFIS) and The Jeffrey Modell Foundation (JMF).

            “We call upon the European Commission DG Consumer Health & Protection,
            to urgently take action to ensure that PIDs are named as a priority for action
                     in rare diseases within the EU’s Public Health Programme”.
Antonios Trakatellis MEP, Philip Whitehead MEP, John Bowis MEP, Caroline Jackson MEP, Cecilia Malmström MEP, Godelieve
   Quisthoudt-Rowohl MEP, Peter Liese MEP, Stephen Hughes MEP, Catherine Stihler MEP, Chris Davies MEP. May 2004.


              INTRODUCTION                                                                                                                                                                                                                             THE ISSUE

  • Primary Immunodeficiencies (PIDs) are a group of more than 100 diseases of the immune                                          • Treatment in the form of bone marrow transplantation and antibody replacement therapies                       The core issue facing PIDs is one of chronic underdiagnosis which leads to:
    system.                                                                                                                          (immunoglobulins) are available to treat PIDs. The latter have a long history of proven                       • Long term physical damage among sufferers
  • They are genetic conditions that range in severity and bare the clinical hallmarks of                                            efficacy in reducing infection, leading to reductions in subsequent illness and hospital                      • Detrimental impact on a sufferer’s quality of life
    persistent, recurring infections.                                                                                                admissions.                                                                                                   • Increased use of healthcare resources
  • Delayed diagnosis and insufficient treatment leads to increased morbidity, mortality, and                                      • As a disease group, PIDs are classified as rare diseases, with an estimated EU prevalence
    inflated medical costs - not to mention a life of chronic illness, permanent organ damage,                                       of 1:10,000.
    disability or even death.                                                                                                      • However experts have stated that up to 70-90% of PIDs remain undiagnosed, with real
  • PIDs can appear at any age and know no racial or ethnic boundaries. Symptoms are often                                           prevalence rates of some PIDs estimated as high as 1:500.1
    overlooked because they appear to be common childhood illnesses - sinus and ear
    infections, pneumonia, fever and bronchitis. Physicians often treat ailments without
                                                                                                                                   1
                                                                                                                                       Prof L Hammarström, Presentation to Scientific & Technical Options Assessment Unit (STOA) of the European
                                                                                                                                       Parliament “Prevalence of PIDs in the EU” March 2004.
                                                                                                                                                                                                                                                       BENEFITS OF EARLY DIAGNOSIS
    addressing the underlying cause.
  • A simple and inexpensive blood test can identify over 95% of PI diseases.
                                                                                                                                                                                                                                                   • PIDs range in severity from complete lack of immune effector cells and severe antibody
                                                                                                                                                                                                                                                     deficiency at one end of the spectrum to partial antibody deficiency at the other.
                                                                                                                                                                                                                                                   • Whichever the severity of the PID, evidence and literature shows that early diagnosis can
                                                                                                                                                                                                                                                     have a positive impact on the health and quality of life of the sufferer, as well as healthcare
                                                                                                                                                                                                                                                     resource.




              EVIDENCE OF HEALTH & HEALTHCARE                                                                                                                                                                                                          INITIATIVES UNDERTAKEN TO RAISE
              RESOURCE BENEFITS                                                                                                                                                                                                                        DIAGNOSIS LEVELS
  In a recent study2, two case histories can be cited as examples how even late diagnosis                                                                                                                                                          The Jeffrey Modell Foundation (JMF) have pioneered public/private awareness and education
  can lead to health benefit and alleviation of healthcare resource use.                                                                                                                                                                           initiatives for PIDs in the US and are working with the PID community in Europe to encourage
  • A 58 year old male was recorded to need 41 days treatment and 8 hospital visits due to                                                                                                                                                         similar schemes in the EU. This has recently included the European Day of Immunology
     infections leading to COPD, bronchitis, pneumonia and sepsis over 18 months between                                                                                                                                                           (http://www.dayofimmunology.org/).
     2000-2001. Once diagnosed with an immune deficiency in 2001 and treated, treatment
     days were reduced to 16, with 5 hospital visits and no hospitalisations over the following                                                                                                                                                    Core JMF awareness campaign elements include:
     18 months.                                                                                                                                                                                                                                    • Baseline survey
  • A 70 year old female PID sufferer was recorded to have had 166 days treatment, with                                                                                                                                                            • 10 Warning Signs Poster
     18 hospital visits over 18 months between 1997 and 1998. After diagnosis, treatment                                                                                                                                                           • Physician Algorithm
     lead to a 500% decrease in treatment days over the following 18 month period and over                                                                                                                                                         • Acquisition of target mailing lists
     300% decrease in the number of hospital visits.                                                                                                                                                                                               • “What you need to know” brochure
    2
            Olinder-Nielsen AM, Forsberg P, Granert C, Vietorisz A, Björkander J, Ig prophylaxis in 350 adults with IgG subclass                                                                                                                   • Coordination with local patient organisations
            deficiency and recurrent respiratory tract infections; 2000 patient-years.                                                                                                                                                             • Educational symposia for clinicians
                                                                                                                                                                                                                                                   • Television, radio & print materials
              KEY CONCLUSIONS                                                                                                                                                                                                                      • Website enhancement and links
                                                                                                                                                                                                                                                   • CD Rom for New Patients
  • About 70% of patients with antibody deficiencies respond well to treatment with antibody                                                                                                                                                       • School nurse poster
    replacement therapy (immunoglobulins) with decreased number of infections and increased
    wellbeing.
  • Undiagnosed and untreated PID patients need greater use of hospital services.
                                                                                                                                                                                                                                                       THE SUCCESS OF THE JMF AWARENESS
                                                                                                                                                                                                                                                       & EDUCATION PROGRAMME
              EVIDENCE OF QUALITY OF LIFE BENEFITS                                                                                                                                                                                                 • Between June 2003 and February 2004, the JMF media campaign reached 129,754,760
                                                                                                                                                                                                                                                     households which lead to an increase of monthly hits on the JMF web site reaching
                                                                                                                                                                                                                                                     565,527 and a monthly increase of 488 calls to their hotline.
  Numerous studies (detailed in table below) have consistently shown that diagnosis and
  treatment leads to improved quality of life for PID sufferers of all ages.

      Year             Authors                               Journal                           Patients
      1993             Gardulf, Björvell,                    Clin Exp Immunol                  Adults (18-66 years)                                                                                                                                    JMF SPECIALIST DIAGNOSTIC CENTRES
                       Gustafson,                                                              Sweden
                       Hammarström, Smith
                                                                                                                                                                                                                                                   • The JMF have pioneered the establishment of a global network of specialist PID diagnostic
      1995             Gardulf, Björvell,                    J Adv Nurs                        Adults (18-76 years)                                                                                                                                  centres which have been instrumental in improving diagnosis and treatment for sufferers
                       Andersen, Bjorkander,                                                   Denmark, Norway,                                                                                                                                      of PIDs. US centres are public/private partnerships, and European specialist diagnostic
                       Ericson, Frøland et al                                                  Sweden                                                                                                                                                centres are now established in Germany, France and Sweden. EU PID specialists are now
      2003             Höybråten Sigstad                     PhD-thesis, Oslo                  Adults (23-76 years)                                                                                                                                  looking for greater involvement of public health bodies to broaden this network across
                                                             University, Norway                Norway                                                                                                                                                the EU.
      2004             Gardulf, Nicolay           J Allergy Clin Immunol                       Children (3-13 years)
                       Asensio, Bernatowska                                                    Adults (14-74 years)
                       Böck, Costa-Carvalho et al                                              Europe

  3
      Gardulf, Björvell, Gustafson et al. Clin Exp Immunol 1993;92:200-4                                                                 CONCLUSIONS
                                                    3
                                                                                                                                                                                                                                                     The EU PID community, represented by the
  The most recent of these studies clearly demonstrate that adults with PIDs have a worse
  Quality of Life (QoL) as compared to healthy individuals (the higher the Sickness Impact                                                                                                                                                           organisations presenting this poster, are working
  (SIP) score, the worse the QoL) and those with a PID have a better QoL once treatment has                                        • “Primary Immunodeficiencies are a serious public                                                                to encourage co-operation with EU and national
  started.                                                                                                                           health concern and (we) recommend a scientific                                                                  health policy makers for recognition of PIDs as a
                           PI Adults                                                   Before IgG treatment                          framework to advance physician education and
                                                                                                                                                                                                                                                     European public health issue in order to alleviate
                           Healthy                                                     SCIG treatment 18 months                      public awareness of PIDs”
            30                                                                   30
                                                                                                                                     US Centre for Disease Control 2001                                                                              the problem of chronic under diagnosis.
SIP score




                                                                     SIP score




            20                                                                   20
                                                                                                                                   • At the European Parliament, a hearing on PIDs held
            10                                                                   10                                                  by the Parliament’s Scientific and Technological
             0                                                                   0
                                                                                                                                     Assessment Unit (STOA) concluded that PIDs should
                                                                                                                                     be prioritised within the EU’s Public Health
                        on




                                                                                            on
             We ity




                                                                                 We lity
                          l




                                                                                              l
                        ue




                                                                                            ue
                         g




                                                                                             g
                        rk




                                                                                            rk
                      cia




                                                                                          cia
                     ein




                                                                                         ein
                    Wo




                                                                                        Wo
                    bil




                    ati




                                                                                        ati
                    tig




                                                                                        tig
                                                                                        bi
                   So




                                                                                       So
                ll-b




                                                                                    ll-b
                Mo




                                                                                    Mo




                                                                                                                                     Programme. March, 2004
                cre




                                                                                    cre
                 Fa




                                                                                     Fa
             Re




                                                                                 Re




  More recently QoL among adults and children with PIDs has been shown to improve with
  the growing use of Home Therapy. Home therapy has also been shown to have cost benefits                                          • A resolution signed by cross party and pan European
  as well.4 QoL related patient feedback in a recent study5 included:
  • “I can travel without any problems. Now I feel I can contribute to my own well-being,                                            Members of the European Parliament called for the
    I am no longer just a ’patient’ or a ’case’.” (Woman , aged 27)                                                                  prioritization of PIDs within the EU’s Public Health
  • “You feel less sick when you don’t have to visit the hospital so often. Freedom!”
    (Man, aged 29)                                                                                                                   Programme. May, 2004
  • “I find the home treatment outstanding. Now I live a normal life and I don’t feel disabled
    any longer. It makes me so happy.” (Woman , aged 51)
  • “Home treatment gives me the opportunity to live like a ’normal’ human being. If anyone                                        • The JMF success has lead the US Congress to cite
    feels disabled by their antibody deficiency, home treatment reduces this feeling to a
    minimum.” (Man, aged 62)                                                                                                         them as: “a model of public-private cooperation
  4
    Gardulf, Möller, Jonsson Int. J. of Technology Assessment in Health Care 1995;11:345-53                                          which should include an International component.
  5
    Gardulf, Björvell, Andersen, Björkander et al.J Adv Nurs 1995;21:917-27
                                                                                                                                     The Committee has included $2,200,000 to continue
              KEY CONCLUSIONS                                                                                                        this campaign, which has great importance to public
  • After treatment, the Sickness Impact (SIP) score for sufferers is shown to improve                                               health.” September, 2004
    dramatically.
  • Home therapy leads to improvements in a patient’s feeling of independence, freedom,
    flexibility, sense of feeling less sick/disabled and results in less time spent away from                                                                                                                                                      IPOPI: http://www.ipopi.org - ESID: http://www.esid.org - JMF: http://www.jmfworld.com
    school and work.                                                                                                                                                                                                                                                INGID: http://www.ingid.org - EFIS: http://www.efis.org

				
DOCUMENT INFO